pfizer glp 1 news Phase IIb Data Support Monthly GLP-1 Dosing for Obesity Pfizer's Monthly GLP-1 Push Tests
Description
In terms of switching, 22.9% of the GLP-1 receptor agonist users and 2.1% of the SGLT2 inhibitor users switched between drugs within the same drug class
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor and mainstay therapeutic target for the treatment of type 2 diabetes and obesity
In todays newsletter: A new study shows that people dont just regain weight after stopping GLP-1 drugs, they see other positive health markers reverse leading to questions about long-term impacts and solutions
Weight loss injections seem to be more popular, but "compounded" versions of these drugs can vary in how people access them.
Theres no cure for RLS
Emerging research, treatment potential, survival impact, and what it means for future cancer therapy.
